Inhaled nano-based therapeutics for pulmonary fibrosis: recent advances and future prospects

[1]  R. Koh,et al.  An Overview of Herbal Medicines for Idiopathic Pulmonary Fibrosis , 2022, Processes.

[2]  Zhongyu Li,et al.  Inhaled siRNA nanoparticles targeting IL11 inhibit lung fibrosis and improve pulmonary function post-bleomycin challenge , 2022, Science advances.

[3]  Xin Zhang,et al.  Exploring the intrinsic micro-/nanoparticle size on their in vivo fate after lung delivery. , 2022, Journal of controlled release : official journal of the Controlled Release Society.

[4]  C. Figueira,et al.  COVID-19 beyond DAD: Persisting microcirculation thrombosis, hidden infections, and early pulmonary fibrosis as remaining challenges of the disease , 2022, Human Pathology Reports.

[5]  C. Hung,et al.  Pharmacological Role of Functionalized Gold Nanoparticles in Disease Applications , 2022, Molecules.

[6]  P. Meskell,et al.  The experience of people with idiopathic pulmonary fibrosis living through the COVID-19 pandemic. , 2022, Journal of advanced nursing.

[7]  Jibiao Wu,et al.  Inhaled mRNA Nanoformulation with Biogenic Ribosomal Protein Reverses Established Pulmonary Fibrosis in a Bleomycin‐Induced Murine Model , 2022, Advanced materials.

[8]  Xin Zhang,et al.  Elucidating inhaled liposome surface charge on its interaction with biological barriers in the lung. , 2022, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[9]  J. Pourchez,et al.  Nano-delivery to the lung - by inhalation or other routes and why nano when micro is largely sufficient? , 2022, Advanced drug delivery reviews.

[10]  G. Zhu,et al.  Pulmonary delivery of mucosal nanovaccines , 2021, Nanoscale.

[11]  M. O. Mahmoud,et al.  Intratracheally Inhalable Nifedipine-Loaded Chitosan-PLGA Nanocomposites as a Promising Nanoplatform for Lung Targeting: Snowballed Protection via Regulation of TGF-β/β-Catenin Pathway in Bleomycin-Induced Pulmonary Fibrosis , 2021, Pharmaceuticals.

[12]  M. Caminati,et al.  The pathogenesis, epidemiology and biomarkers of susceptibility of pulmonary fibrosis in COVID-19 survivors , 2021, Clinical chemistry and laboratory medicine.

[13]  S. M. Badr-Eldin,et al.  Aerosol Delivery of Surfactant Liposomes for Management of Pulmonary Fibrosis: An Approach Supporting Pulmonary Mechanics , 2021, Pharmaceutics.

[14]  A. Maleki,et al.  Pectin/chitosan/tripolyphosphate encapsulation protects the rat lung from fibrosis and apoptosis induced by paraquat inhalation. , 2021, Pesticide biochemistry and physiology.

[15]  J. Sharifi‐Rad,et al.  Chitosan nanoparticles as a promising tool in nanomedicine with particular emphasis on oncological treatment , 2021, Cancer Cell International.

[16]  Kristen D. Popowski,et al.  Cell-Mimicking Nanodecoys Neutralize SARS-CoV-2 and Mitigate Lung Injury in a Nonhuman Primate Model of COVID-19 , 2021, Nature Nanotechnology.

[17]  A. Hemmati,et al.  The Protective Effects of Nebulized Nano-Curcumin Against Bleomycin-Induced Pulmonary Fibrosis in Rats , 2021, Jundishapur Journal of Natural Pharmaceutical Products.

[18]  Jyothi U. Menon,et al.  Emerging Drug Delivery Strategies for Idiopathic Pulmonary Fibrosis Treatment. , 2021, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[19]  S. Jon,et al.  Biomimetic lipid Nanocomplexes incorporating STAT3-inhibiting peptides effectively infiltrate the lung barrier and ameliorate pulmonary fibrosis. , 2021, Journal of controlled release : official journal of the Controlled Release Society.

[20]  Z. Yousaf,et al.  Post COVID-19 fibrosis, an emerging complicationof SARS-CoV-2 infection , 2020, IDCases.

[21]  Ashish Jain,et al.  Nanotoxicity: The Dark Side of Nanoformulations , 2020 .

[22]  Seungpyo Hong,et al.  Nanoapproaches to Modifying Epigenetics of Epithelial Mesenchymal Transition for Treatment of Pulmonary Fibrosis , 2020, Frontiers in Pharmacology.

[23]  Ping Yang,et al.  MBD2 serves as a viable target against pulmonary fibrosis by inhibiting macrophage M2 program , 2020, Science Advances.

[24]  S. Cuzzocrea,et al.  Loading Imatinib inside targeted nanoparticles to prevent Bronchiolitis Obliterans Syndrome , 2020, Scientific Reports.

[25]  Guiqiang Wang,et al.  Discharge may not be the end of treatment: Pay attention to pulmonary fibrosis caused by severe COVID‐19 , 2020, Journal of medical virology.

[26]  Jiaqi Yu,et al.  A dry powder inhalable formulation of salvianolic acids for the treatment of pulmonary fibrosis: safety, lung deposition, and pharmacokinetic study , 2020, Drug Delivery and Translational Research.

[27]  L. Dailey,et al.  Tuberculosis Treatment Facilitated by Lipid Nanocarriers: Can Inhalation Improve the Regimen? , 2020, Assay and drug development technologies.

[28]  H. Tada,et al.  Prolonged distribution of aerosolized PEGylated liposomes in the lungs of mice with bleomycin-induced pulmonary fibrosis , 2020, Drug development and industrial pharmacy.

[29]  F. Tacke,et al.  Dexamethasone nanomedicines for COVID-19 , 2020, Nature Nanotechnology.

[30]  R. Williams,et al.  Inhaled nanoparticles-An updated review. , 2020, International journal of pharmaceutics.

[31]  M. Fear,et al.  The extracellular matrix and mechanotransduction in pulmonary fibrosis. , 2020, The international journal of biochemistry & cell biology.

[32]  Yongjun Liu,et al.  A Review on Nano-Based Drug Delivery System for Cancer Chemoimmunotherapy , 2020, Nano-micro letters.

[33]  T. Luckhardt,et al.  Updated Evaluation of the Safety, Efficacy and Tolerability of Pirfenidone in the Treatment of Idiopathic Pulmonary Fibrosis , 2020, Drug, healthcare and patient safety.

[34]  N. Sağlam,et al.  Nanotoxicity: a challenge for future medicine , 2020, Turkish journal of medical sciences.

[35]  Xiaomin Deng,et al.  Inhalation of Tetrandrine- hydroxypropyl-β-cyclodextrin Inclusion Complexes for Pulmonary Fibrosis Treatment. , 2020, Molecular pharmaceutics.

[36]  Xinxia Peng,et al.  Inhalation of lung spheroid cell secretome and exosomes promotes lung repair in pulmonary fibrosis , 2020, Nature Communications.

[37]  Yuqiang Ma,et al.  Neutrophil membranes coated, antibiotic agent loaded nanoparticles targeting to the lung inflammation. , 2019, Colloids and surfaces. B, Biointerfaces.

[38]  Eoin Casey,et al.  Nanoparticle-Biofilm Interactions: The Role of the EPS Matrix. , 2019, Trends in microbiology.

[39]  M. Morosini,et al.  Imatinib-loaded gold nanoparticles inhibit proliferation of fibroblasts and macrophages from systemic sclerosis patients and ameliorate experimental bleomycin-induced lung fibrosis. , 2019, Journal of controlled release : official journal of the Controlled Release Society.

[40]  M. Morosini,et al.  Hyaluronic Acid–Decorated Liposomes as Innovative Targeted Delivery System for Lung Fibrotic Cells , 2019, Molecules.

[41]  Shinichi Sasaki,et al.  Gastrointestinal adverse effects of nintedanib and the associated risk factors in patients with idiopathic pulmonary fibrosis , 2019, Scientific Reports.

[42]  R. Zeng,et al.  Pulmonary delivery of therapeutic proteins based on zwitterionic chitosan-based nanocarriers for treatment on bleomycin-induced pulmonary fibrosis. , 2019, International journal of biological macromolecules.

[43]  M. Kratochvil,et al.  Hydrogel-based delivery of Il-10 improves treatment of bleomycin-induced lung fibrosis in mice. , 2019, Biomaterials.

[44]  C. Sevinç,et al.  The Effectiveness, Safety, and Tolerability of Pirfenidone in Idiopathic Pulmonary Fibrosis: A Retrospective Study , 2019, Advances in Therapy.

[45]  J. Cortijo,et al.  Idiopathic Pulmonary Fibrosis and Lung Cancer: Mechanisms and Molecular Targets , 2019, International journal of molecular sciences.

[46]  A. Sood,et al.  Metal-Induced Pulmonary Fibrosis , 2018, Current Environmental Health Reports.

[47]  Leonardo Fernandes Fraceto,et al.  Nano based drug delivery systems: recent developments and future prospects , 2018, Journal of Nanobiotechnology.

[48]  D. Oupický,et al.  Pulmonary delivery of polyplexes for combined PAI-1 gene silencing and CXCR4 inhibition to treat lung fibrosis. , 2018, Nanomedicine : nanotechnology, biology, and medicine.

[49]  R. Murali,et al.  Nano-Toxicity: A Bird’s Eye View of Toxicological Aspects , 2018, Research & Development in Material Science.

[50]  R. Saha,et al.  Nanostructured lipid carriers for site-specific drug delivery. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[51]  A. Gemma,et al.  Japanese guideline for the treatment of idiopathic pulmonary fibrosis. , 2018, Respiratory investigation.

[52]  Chunru Wang,et al.  Inhalable gadofullerenol/[70] fullerenol as high-efficiency ROS scavengers for pulmonary fibrosis therapy. , 2018, Nanomedicine : nanotechnology, biology, and medicine.

[53]  J. Backman,et al.  Pulmonary administration of a dry powder formulation of the antifibrotic drug tilorone reduces silica‐induced lung fibrosis in mice , 2018, International journal of pharmaceutics.

[54]  G. Raghu,et al.  Lung transplantation in idiopathic pulmonary fibrosis , 2018, Expert review of respiratory medicine.

[55]  L. Richeldi,et al.  Idiopathic pulmonary fibrosis: pathogenesis and management , 2018, Respiratory Research.

[56]  Jia-You Fang,et al.  Inhalable particulate drug delivery systems for lung cancer therapy: Nanoparticles, microparticles, nanocomposites and nanoaggregates. , 2018, Journal of controlled release : official journal of the Controlled Release Society.

[57]  E. Wasan,et al.  An Overview of Chitosan Nanoparticles and Its Application in Non-Parenteral Drug Delivery , 2017, Pharmaceutics.

[58]  Megan Logan,et al.  Biocompatibility of hydrogel-based scaffolds for tissue engineering applications. , 2017, Biotechnology advances.

[59]  Rohan S. Virgincar,et al.  Using hyperpolarized 129Xe MRI to quantify regional gas transfer in idiopathic pulmonary fibrosis , 2017, Thorax.

[60]  E. Bhargav,et al.  Pulmonary delivery of liposomal dry powder inhaler formulation for effective treatment of idiopathic pulmonary fibrosis , 2017, Asian journal of pharmaceutical sciences.

[61]  G. Criner,et al.  Pirfenidone and nintedanib for pulmonary fibrosis in clinical practice: Tolerability and adverse drug reactions , 2017, Respirology.

[62]  K. Reuhl,et al.  Combinatorial treatment of idiopathic pulmonary fibrosis using nanoparticles with prostaglandin E and siRNA(s). , 2017, Nanomedicine : nanotechnology, biology, and medicine.

[63]  Youqing Shen,et al.  Rational Design of Cancer Nanomedicine: Nanoproperty Integration and Synchronization , 2017, Advanced materials.

[64]  A. Zimmer,et al.  Itraconazole-loaded nanostructured lipid carriers (NLC) for pulmonary treatment of aspergillosis in falcons. , 2016, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[65]  David J. Mooney,et al.  Designing hydrogels for controlled drug delivery. , 2016, Nature reviews. Materials.

[66]  Y. Zhou,et al.  Atomized paclitaxel liposome inhalation treatment of bleomycin-induced pulmonary fibrosis in rats. , 2016, Genetics and molecular research : GMR.

[67]  Ali Khademhosseini,et al.  Functionalization, preparation and use of cell-laden gelatin methacryloyl–based hydrogels as modular tissue culture platforms , 2016, Nature Protocols.

[68]  A. Elhissi,et al.  Liposome Delivery Systems for Inhalation: A Critical Review Highlighting Formulation Issues and Anticancer Applications , 2016, Medical Principles and Practice.

[69]  Eun Seong Lee,et al.  Treatment of bleomycin-induced pulmonary fibrosis by inhaled tacrolimus-loaded chitosan-coated poly(lactic-co-glycolic acid) nanoparticles. , 2016, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[70]  H. Takeuchi,et al.  Inhalation properties of water-soluble drug loaded liposomes atomized by nebulizer , 2016 .

[71]  Eun Seong Lee,et al.  Therapeutic advantage of inhaled tacrolimus-bound albumin nanoparticles in a bleomycin-induced pulmonary fibrosis mouse model. , 2016, Pulmonary pharmacology & therapeutics.

[72]  Andriy Kuzmov,et al.  Nanotechnology approaches for inhalation treatment of lung diseases. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[73]  Daniela Traini,et al.  Inhalation of nanoparticle-based drug for lung cancer treatment: Advantages and challenges , 2015 .

[74]  Jaime Conceição,et al.  Nanotechnological carriers for cancer chemotherapy: the state of the art. , 2015, Colloids and surfaces. B, Biointerfaces.

[75]  E. Mancl,et al.  Recent Evidence for Pharmacological Treatment of Idiopathic Pulmonary Fibrosis , 2014, The Annals of pharmacotherapy.

[76]  V. Pokharkar,et al.  Montelukast-loaded nanostructured lipid carriers: part II pulmonary drug delivery and in vitro-in vivo aerosol performance. , 2014, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[77]  Ling Zhao,et al.  Passive lung-targeted drug delivery systems via intravenous administration , 2014, Pharmaceutical development and technology.

[78]  R. Dunmore,et al.  The epithelium in idiopathic pulmonary fibrosis: breaking the barrier , 2014, Front. Pharmacol..

[79]  M. Rojas,et al.  Inhibition of the CXCL12/CXCR4-Axis as Preventive Therapy for Radiation-Induced Pulmonary Fibrosis , 2013, PloS one.

[80]  K. Reuhl,et al.  Inhalation treatment of pulmonary fibrosis by liposomal prostaglandin E2. , 2013, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[81]  D. Riches,et al.  Local delivery of biodegradable pirfenidone nanoparticles ameliorates bleomycin-induced pulmonary fibrosis in mice , 2012, Nanotechnology.

[82]  Jing Geng,et al.  Inhibiting CXCR4/CXCL12 axis attenuates lung fibrosis both in vitro and in vivo , 2012 .

[83]  Hirenkumar K. Makadia,et al.  Poly Lactic-co-Glycolic Acid ( PLGA ) as Biodegradable Controlled Drug Delivery Carrier , 2011 .

[84]  K. Pathak,et al.  Nanostructured lipid carrier versus solid lipid nanoparticles of simvastatin: comparative analysis of characteristics, pharmacokinetics and tissue uptake. , 2011, International journal of pharmaceutics.

[85]  Thomas A. Wynn,et al.  Integrating mechanisms of pulmonary fibrosis , 2011, The Journal of experimental medicine.

[86]  U. Schubert,et al.  Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. , 2010, Angewandte Chemie.

[87]  Jeffrey W Card,et al.  Pulmonary applications and toxicity of engineered nanoparticles. , 2008, American journal of physiology. Lung cellular and molecular physiology.

[88]  M. Rojas,et al.  Role of the SDF-1/CXCR4 axis in the pathogenesis of lung injury and fibrosis. , 2007, American journal of respiratory cell and molecular biology.

[89]  Barrett E. Rabinow,et al.  Nanosuspensions in drug delivery , 2004, Nature Reviews Drug Discovery.

[90]  Thomas Kissel,et al.  In vitro cytotoxicity testing of polycations: influence of polymer structure on cell viability and hemolysis. , 2003, Biomaterials.

[91]  Ying-zheng Zhao,et al.  Progress in the Application of Nano- and Micro-based Drug Delivery Systems in Pulmonary Drug Delivery , 2021, BIO Integration.

[92]  Yao.  Progress in the Application of Nano- and Micro-based Drug Delivery Systems in Pulmonary Drug Delivery , 2021 .

[93]  M. Molina-Molina.  The Future of Pharmacological Treatment in Idiopathic Pulmonary Fibrosis. , 2019 .

[94]  A. Zimmer,et al.  Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC) for pulmonary application: a review of the state of the art. , 2014, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[95]  S. Rosselot.  Idiopathic pulmonary fibrosis. , 2014, Nursing standard (Royal College of Nursing (Great Britain) : 1987).